Thorium dioxide
- PDF / 130,622 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 28 Downloads / 192 Views
1
S
Chronic liver disease in an elderly patient: case report An 83-year-old woman developed chronic liver disease following administration of the contrast agent Th orotrast, a radioactive suspension containing thorium dioxide [dosage and outcome not stated; time to reaction onset not clearly stated]. The woman, who had received Th orotrast for imaging of a cirosoidal aneursym in the 1950’s, presented with recurrent ascites and chronic liver disease. She underwent paracentesis, which revealed fluid with a serum-ascites albumin gradient >1.1, suggestive of portal hypertension. She had thrombocytopenia, and an abdominal CT showed liver cirrhosis with prominent, contrast-enhancing high density material in the spleen and peripancreatic lymph nodes. A transjugular liver biopsy showed periportal fibrosis and focal granular foreign body material. Author comment: "[I]t was discovered that Th orotrast induced liver disease and tumors decades after its use. Our case is unique in that Th orotrast-induced chronic liver disease is seldom seen in modern-day clinical practice." Habib I, et al. Th orotrast-induced chronic liver disease: A rare finding in today’s clinical practice. American Journal of Gastroenterology 108: S347, Oct 2013. Available from: URL: http://dx.doi.org/10.1038/ajg.2013.267 [abstract] 803096327 USA
0114-9954/13/1480-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Reactions 30 Nov 2013 No. 1480
Data Loading...
